FULGENT GENETICS, INC. (NASDAQ:FLGT) Files An 8-K Submission of Matters to a Vote of Security Holders

Item 5.07Submission of Matters to a Vote of Security Holders.

On May 16, 2017, Fulgent Genetics, Inc. (the Company) held its
2017 Annual Meeting of Stockholders (Annual Meeting) at its
principal executive offices. An aggregate of 17,676,256 shares of
the Companys common stock were outstanding as of March 24, 2017,
the record date for the Annual Meeting, and entitled to vote at
the Annual Meeting. Of these shares, 13,888,119 shares were
present in person or by proxy at the Annual Meeting, constituting
a quorum of 79%. The Companys stockholders considered and voted
on three proposals at the Annual Meeting and cast their votes on
each proposal as set forth below.

Proposal 1: To elect four directors, each to serve a one-year
term until the next annual meeting of the Companys stockholders
and until his successor is duly elected and qualified. The
results of the voting on Proposal 1 were as follows:

Proposal 2: To ratify the appointment of Deloitte Touche LLP as
the Companys independent registered public accounting firm for
the fiscal year ending December 31, 2017. The results of the
voting on Proposal 2 were as follows:

Proposal 3: To approve an amendment to the Companys certificate
of incorporation to reduce the number of shares of common stock
that the Company is authorized to issue from 200,000,000 to
50,000,000. The results of the voting on Proposal 3 were as
follows:

About FULGENT GENETICS, INC. (NASDAQ:FLGT)

Fulgent Genetics, Inc. is a technology company. The Company offers genetic testing to provide physicians with clinically actionable diagnostic information to improve quality of patient care. The Company has developed a technology platform that integrates data comparison and suppression algorithms, adaptive learning software, advanced genetic diagnostics tools and integrated laboratory processes. As of December 31, 2015, the Company’s test menu includes approximately 18,000 single-gene tests and over 200 pre-established, multi-gene, disease-specific panels that collectively test for approximately 7,500 genetic conditions, including various cancers, cardiovascular diseases and neurological disorders. The Company’s gene probes are specifically engineered to generate genetic data that is optimized for its software, which enables to rapidly incorporate new genes into its test menu, develop new panels of disease-specific tests and customize tests for its customers.

FULGENT GENETICS, INC. (NASDAQ:FLGT) Recent Trading Information

FULGENT GENETICS, INC. (NASDAQ:FLGT) closed its last trading session down -0.23 at 6.80 with 28,693 shares trading hands.